Huntington’s Disease Treatment Market

Huntington’s Disease Treatment Market by Treatments (Symptomatic Therapy and Disease-modifying Therapy), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1112
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 3
  • No. Of Pages: 184
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global Huntington’s disease treatment market size is anticipated to register a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing improved symptomatic therapies, growing targeted population, and promising disease-modifying therapies in the developmental pipeline.
 

Huntington’s Disease Treatment Market Key Takeaways


Huntington’s disease (HD) is a hereditary neurodegenerative disorder of the central nervous system which is categorized by combination of motor, cognitive, and psychiatric symptoms. Results of this disease is progressive degeneration of the brain cells. In 1872, a physician named George Huntington, described the disorder as a hereditary chorea. Hence, earlier it was called as Huntington’s chorea or HC.

The symptoms of Huntington’s disease generally developed in adulthood between the age of 30 years and 40 years. If the symptoms developed before 20 years then it is called as juvenile Huntington’s disease. In the U.S., every year around 30,000 cases of HD are found and approximately, 15% of all cases are affected by Juvenile HD. Both men and women are equally affected. The disease causes several different symptoms in patient which leads to trouble in motor control (movement), cognition (thinking), and behavior.

Patients having HD also has muscle problems such as posture, muscle contracture (dystonia) or rigidity, balance, and impaired gait. Cognition disorder and substantial behavior related to HD is depression which results because of brain injury and loss of brain function. Presently, Xenazine and Austedo are only two symptom-alleviating therapies which are approved for HD. The market inclination of drug-development approach is shifting from conventional symptomatic therapies to disease-modifying therapies. This is driven by the pathogenesis of this disorder.

Market Trends, Drivers, Restraints, and Opportunities

  • Growing prevalence of Huntington’s disease and rising research and development programs in various institutes and universities are projected to drive the market expansion in the coming years.
  • Increasing improved symptomatic therapies and rising pipelines of novel therapies are anticipated to fuel the market growth.
  • Unmet medical needs and rising awareness about Huntington’s disease are expected to propel the expansion of the market during the forecast period.
  • Rising investments in research and development sector by various pharmaceutical companies is estimated to spur the market growth in the coming years.
  • Presence of alternative therapies such as speech therapy, psychotherapy, and physiotherapy are projected to boost the market growth.
  • Stringent regulations and limited approved drug are major factor responsible for hampering the growth of the market in the coming years.

Scope of the Report

The report on the global Huntington’s disease treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Huntington’s Disease Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Treatments (Symptomatic Therapy and Disease-modifying Therapy)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Valeant Pharmaceuticals, Teva Pharmaceuticals, Wave Life Sciences, Ionis Pharmaceuticals/ Roche, Raptor Pharmaceuticals, Prana Biotechnology, Alnylam Pharmaceuticals, Inc., AmpliPhi Biosciences Corp, Pfizer, Lundbeck, Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, GlaxoSmithKline, Auspex Pharmaceuticals, Ceregene Inc., SOM Biotech, Siena Biotech, Palobiofarma, and Ipsen

 

Market Segment Insights

Disease-modifying therapy segment is expected to grow at a significant pace
Based on treatments, the Huntington’s disease treatment market is bifurcated into symptomatic therapy and disease-modifying therapy. The symptomatic treatment segment is expected to hold a key share of the market during the forecast period. In this treatment drugs are used such as tetrabenazine, antidepressants, antipsychotic or mood-stabilizing. Moreover, speech therapy, home remedies, psychotherapy, occupational therapy or lifestyle, and physical therapy are important for the improvement in the life of the patient.

However, the disease-modifying therapy segment is anticipated to expand at a rapid pace during the forecast period owing to launch of several novel products and rising R&D sector. Presently, research in HD targets on use of novel treatments including immuno-modulating therapies and gene therapy such as zinc-finger DNA binding protein (ZFP), antisense oligonucleotides, mRNA splicing, and micro RNAs (miRNA).
 

Huntington’s Disease Treatment Market By Treatments


North America is expected to dominate the market
On the basis of regions, the Huntington’s disease treatment market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to increasing adoption of novel therapeutics, presence of major market players, and multiple product launches. Furthermore, rising activities in R&D sector, increasing investment by pharmaceutical companies in the region are expected to fuel the market growth in the coming years. Also, more effective and improved drugs, innovative and advanced technology, and increasing number of vendors are projected to drive the market expansion.

On the other hand, the market of Europe is expected to exhibit a rapid growth rate in the coming years owing to rising awareness of disease among people and increasing infrastructure for scientific research.
 

Huntington’s Disease Treatment Market By Regions

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Huntington’s Disease Treatment Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Huntington’s Disease Treatment Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Huntington’s Disease Treatment Market - Supply Chain
  4.5. Global Huntington’s Disease Treatment Market Forecast
     4.5.1. Huntington’s Disease Treatment Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Huntington’s Disease Treatment Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Huntington’s Disease Treatment Market Absolute $ Opportunity
5. Global Huntington’s Disease Treatment Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Huntington’s Disease Treatment Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Huntington’s Disease Treatment Demand Share Forecast, 2019-2026
6. North America Huntington’s Disease Treatment Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Huntington’s Disease Treatment Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Huntington’s Disease Treatment Demand Share Forecast, 2019-2026
7. Latin America Huntington’s Disease Treatment Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Huntington’s Disease Treatment Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Huntington’s Disease Treatment Demand Share Forecast, 2019-2026
8. Europe Huntington’s Disease Treatment Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Huntington’s Disease Treatment Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Huntington’s Disease Treatment Demand Share Forecast, 2019-2026
9. Asia Pacific Huntington’s Disease Treatment Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Huntington’s Disease Treatment Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Huntington’s Disease Treatment Demand Share Forecast, 2019-2026
10. Middle East & Africa Huntington’s Disease Treatment Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Huntington’s Disease Treatment Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Huntington’s Disease Treatment Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Huntington’s Disease Treatment Market: Market Share Analysis
  11.2. Huntington’s Disease Treatment Distributors and Customers
  11.3. Huntington’s Disease Treatment Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Valeant Pharmaceuticals
     11.4.2. Teva Pharmaceuticals
     11.4.3. Wave Life Sciences
     11.4.4. Ionis Pharmaceuticals/ Roche
     11.4.5. Raptor Pharmaceuticals
     11.4.6. Prana Biotechnology
     11.4.7. Alnylam Pharmaceuticals, Inc.
     11.4.8. AmpliPhi Biosciences Corp
     11.4.9. Pfizer
     11.4.10. Lundbeck

Segments Covered in the Report
The global Huntington’s disease treatment market has been segmented on the basis of

Treatments

  • Symptomatic Therapy and
  • Disease-modifying Therapy

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Valeant Pharmaceuticals
  • Teva Pharmaceuticals
  • Wave Life Sciences
  • Ionis Pharmaceuticals/ Roche
  • Raptor Pharmaceuticals
  • Prana Biotechnology
  • Alnylam Pharmaceuticals, Inc.
  • AmpliPhi Biosciences Corp
  • Pfizer
  • Lundbeck
  • Cortex Pharmaceuticals Inc.
  • Vertex Pharmaceuticals Incorporated
  • GlaxoSmithKline
  • Auspex Pharmaceuticals
  • Ceregene Inc.
  • SOM Biotech
  • Siena Biotech
  • Palobiofarma
  • Ipsen

Key players competing in the Huntington’s disease treatment market are Valeant Pharmaceuticals, Teva Pharmaceuticals, Wave Life Sciences, Ionis Pharmaceuticals/ Roche, Raptor Pharmaceuticals, Prana Biotechnology, Alnylam Pharmaceuticals, Inc., AmpliPhi Biosciences Corp, Pfizer, Lundbeck, Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, GlaxoSmithKline, Auspex Pharmaceuticals, Ceregene Inc., SOM Biotech, Siena Biotech, Palobiofarma, and Ipsen.

Major market players are adopting several business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.
 

Huntington’s Disease Treatment MarketBy Key Players

Buy Report